As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Predicting tumor progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

A plant-based compound called sulfuretin is being explored as a potential cancer treatment. Sulfuretin stopped the progression of cancer cells in a lab study. Researchers are doing additional testing ...

Experts discuss the small but promising study.

Drs Dean Ornish and Peter Carroll presented their research on the effects of an intensive lifestyle program on outcomes for ...

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive metastatic breast cancer patients. The PATINA trial showed a median ...

A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...

Significantly longer progression-free survival seen with addition of palbociclib to maintenance anti-HER2 and endocrine therapies.

PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England ...